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ABSTRACT
The type of surgical treatment in breast cancer shows strong regional variation. The 
aim of studies I-III was to specifically investigate causes of the disparity in breast 
conservation and immediate breast reconstruction (IBR) rates in the six Swedish 
healthcare regions. All women who underwent any surgical intervention for primary 
breast cancer in Sweden in 2013 were included. Tumour and treatment data were 
retrieved from the Swedish National Breast Cancer Register, and socioeconomic 
background data from the Central Bureau of Statistics Sweden. Postal questionnaires 
regarding preoperative information and involvement in the preoperative decision-
making process were sent to all mastectomy patients, with a response rate of 76.3%. 
Of 7735 women, 4604 (59.5%) had breast conservation and 3131 (40.5%) mastec-
tomy, 267 of whom also received IBR. While tumour and patient characteristics 
predictably affected surgical treatment, they could not explain regional variations. 
Higher socioeconomic status resulted in a higher rate of IBR and breast conserva-
tion. Patient-reported preoperative information (OR 12.73, 95% Cl 6.03-26.89) and 
involvement in the decision-making process (OR 2.56, 95% Cl 1.14-5.76) remained 
strong independent predictors of IBR even after adjustment for socioeconomic factors. 
After implant-based IBR, primary expander devices are frequently exchanged for 
permanent silicone implants. The aim of study IV was to assess whether the  timing 
of this exchange procedure in relation to the completion of post-mastectomy radio-
therapy (PMRT) and other clinical factors affect surgical complications rates result-
ing in implant failure (primary outcome). All women previously treated with an IBR 
who underwent implant exchange and/or capsulectomy at Karolinska University 
Hospital between 2005 and 2015 were included. Detailed information was collected 
through individual medical chart review. The final cohort consisted of 475 breast 
cancer patients with 707 implant revision surgeries in 542 breasts, in which 33 cases 
of implant failure were observed. PMRT, smoking and diabetes were confirmed 
as risk factors, while time from completion of PMRT to revision surgery was not 
associated with the outcome. Additional risk factors were a previous axillary lymph 
node dissection and a history of a post-IBR infection. 
A common problem in implant-based IBR is the development of a capsular con-
tracture secondary to PMRT. Study V evaluated gene expression patterns in biop-
sies from irradiated (n=13) and non-irradiated (n=12) capsular tissue harvested 
during implant exchange surgery in IBR patients, and gene expression levels were 
compared in order to identify the most differentially regulated genes in order to 
explore the underlying biology with the wider aim to generate knowledge enabling 
the development of therapeutic strategies. Radio-responsive genes were most often 
involved in inflammation immune response, and both innate and adaptive immune 
system responses were confirmed by immunohistochemistry on the protein level. 
There was a significant upregulation in CD20+ B-cell counts in irradiated biopsies, 
which was supported by gene expression analysis. However, the findings need to 
be confirmed in a larger study. 
POPULÄRVETENSKAPLIG SAMMANFATTNING
Den primära behandlingen av bröstcancer är i de flesta fall kirurgi. Vilken typ av 
kirurgisk behandling som patienterna erhåller varierar stort mellan de olika sjuk-
vårdsregionerna. I studierna I-III var syftet att studera orsakerna till skillnaderna 
i frekvens av bröstbevarande kirurgi (BCS) och omedelbar rekonstruktion (IBR). 
Alla kvinnor som opererades för bröstcancer år 2013 identifierades från Nationella 
kvalitetsregistret för bröstcancer. Tumördata och behandlingsdata rekvirerades 
och kopplades till socioekonomiska bakgrundsdata från Statistiska centralbyrån. 
Ett frågeformulär skickades till alla patienter som genomgått en mastektomi 
avseende vilken grad av preoperativ information man erhållit om olika kirurgiska 
behandlings- och rekonstruktionsmetoder och i vilken grad man känt sig delaktig 
i den preoperativa beslutsprocessen. Svarsfrekvensen på enkäten var 76,3 %. Av 
totalt 7735 kvinnor med bröstcancer hade 4604 (59,5 %) opererats med BCS och 
3131 (40,5 %) med mastektomi, varav 267 också genomgick IBR. Tumörstatus 
påverkade valet av kirurgisk behandling men kunde inte förklara de regionala 
variationerna, däremot fanns det signifikanta skillnader av preoperativ information 
och delaktighet mellan de olika regionerna. Högre socioekonomisk status resul-
terade i en högre frekvens av både omedelbar rekonstruktion och bröstbevarande 
kirurgi. Även efter justering för socioekonomiska faktorer förblev patientrappor-
terad preoperativ information och delaktighet i beslutsprocessen starka oberoende 
prediktorer för IBR.
Oftast innebär en direkt rekonstruktion med implantat flera rekonstruktiva steg. Efter 
implantatbaserad IBR, där man vanligast opererar in en protes som kan expanderas, 
kan denna senare bytas till ett permanent silikonimplantat. Om strålbehandling 
ges mot ett bröst rekonstruerat med implantat innebär det risk för kapselkontraktur 
som innebär att den naturliga kapseln runt protesen blir kraftigare och drar ihop 
sig, vilket leder till kosmetisk försämring men ibland också till smärta. Syftet med 
studie IV var att bedöma den optimala tidpunkten för ett protesbyte eller annan 
revisionskirurgi i själva proteshålan efter avslutad strål behandling samt att studera 
ytterligare kliniska riskfaktorer som påverkar komplikationsfrekvensen, och som 
kan resultera i att protesen behöver avlägsnas. Alla kvinnor som tidigare behandlats 
för bröstcancer med en mastektomi och IBR och sedan genomgick protesbyte och/
eller klyvning av proteskapseln vid Karolinska Universitetssjukhuset mellan 2005 
och 2015 inkluderades. Genom individuell journal granskning samlades detalje-
rad information. Kohorten bestod av 475 kvinnor med 707 revisionsoperationer 
i 542 bröst. Protesen behövde avlägsnas på grund av postoperativa komplikatio-
ner i 33 fall. Strålning mot det rekonstruerade bröstet efter mastektomi (PMRT), 
rökning och diabetes bekräftades som riskfaktorer för protesförlust, medan tiden 
från avslutad PMRT till revisionsoperation inte var relaterat till protesförlust. 
Ytterligare risk faktorer var om patienten genomgått lymfkörtelutrymning vid 
IBR och om  patienten haft en postoperativ infektion i samband med den tidigare 
IBR operationen.
Som beskrivits ovan är utvecklingen av kapselkontraktur ett vanligt problem vid 
implantat-baserad direktrekonstruktion då strålbehandlingen ges postoperativt. 
För att bättre kunna förstå biologin bakom utvecklingen av kapselkontraktur 
utvärderades i studie V genuttrycksmönster i biopsier från strålade (n=13) och 
icke-strålade (n=12) kapselvävnader efter IBR. Dessa biopsier samlades in vid 
operationer där implantatet byttes ut efter tidigare IBR. Man jämförde skillnader 
i genuttryck mellan de båda grupperna för att identifiera de gener som påverkades 
mest av strålningen och fann att många av dessa var involverade i flera inflam-
matoriska processer. Många av de gener som påverkades mest av strålning visade 
sig vara involverade i både det innata och adaptiva immunförsvaret många år efter 
strålbehandling. Immunohistokemisk färgning av inflammatoriska celler gav ytter-
ligare stöd för detta. Särskilt tydligt var en ökad förekomst av i CD20 + B-celler i 
bestrålade biopsier, vilket är intressant mot bakgrund av genuttrycksanalyser som 
visade B-cells medierat immunsvar som ett av de tydligaste resultaten.
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11 LITERATURE REVIEW 
1.1 Breast cancer
Globally, breast cancer ranks as the second most diagnosed cancer, and more than 
1.7 million new cases were registered worldwide in 2015. Breast cancer accounts 
for 10% of global cancer cases and for 22% of all cancer among women. Incidence 
rates are higher in developed countries with about 80 cases per 100,000 women 
and lower in less developed countries with <40 cases per 100,000 women (1). 
Further, they are on the rise in emerging economies, probably owing to a more 
“western-like” lifestyle but also to improved diagnostics (1). Since the last cen-
tury, some decrease in the incidence in developed countries has been seen, which 
might be the result of a declining use of hormone replacement therapy (HRT) (2) 
and of adherence to mammography screening (3). In Sweden, 8400 women were 
diagnosed with breast cancer in 2012, 8630 in 2015, and 8463 in 2016 (4). Survival 
has been increasing in all Western countries during the last three decades. Better 
survival is attributed to the implementation of mammography screening, advance-
ments in adjuvant and neoadjuvant treatments such as chemotherapy, endocrine 
and targeted therapies, to better general healthcare, an increasing degree of self-
examination, and breast cancer awareness (5).
The golden standard for diagnosing breast cancer is triple assessment, which 
includes physical examination, imaging by mammography and/or ultrasound, and 
either fine-needle aspiration cytology or needle biopsy. This diagnostic combina-
tion has a high sensitivity and reaches almost 100% diagnostic accuracy (6). All 
breast cancer patients should be discussed at a multidisciplinary team conference 
both pre- and postoperatively according to Swedish guidelines. Such conferences 
were established in Sweden more than 25 years ago and bring together a breast 
surgeon, breast oncologist, breast radiologist, pathologist, breast nurse and some-
times a plastic surgeon. Based on comprehensive diagnostics and team discussion, 
a treatment recommendation is given. Treatment can include surgery, radiotherapy, 
chemotherapy, endocrine treatment as well as targeted therapies. 
1.1.1 Surgical treatment
William Halsted coined the term “radical mastectomy” in 1892, including removal 
of all breast tissue, overlying skin, pectoral major and minor muscles and axil-
lary lymph nodes (7). In 1948, the operation was modified in order to decrease 
postoperative morbidity and disfigurement by preserving the pectoral major 
muscle, a procedure known as modified radical mastectomy (8). Still, while the 
Halstedian paradigm stated that the cancer would only spread per continuum along 
 lymphatics, and more radical resections would thus lead to better cure, exten-
sive surgery did not decrease mortality. The work by Fisher et al resulted in the 
2notion that breast cancer is rather a systemic than a local disease, a concept still 
valid today (9). Subsequently, as a combined result of better understanding of the 
biology and behaviour of tumours, as well as earlier detection and thus smaller 
tumour sizes, breast-conserving surgery, where only the tumour-bearing part of 
the breast is removed with an appropriate margin, was introduced in the 1970s. In 
randomized multicentre trials with long-term follow-up, breast-conserving surgery 
with subsequent whole-breast radiotherapy (together termed breast-conserving 
therapy, BCT) achieved survival rates comparable to mastectomy despite higher 
local recurrence rates at that time (10,11). Breast-conserving therapy has become 
the golden standard for women with early-stage breast cancer and is today per-
formed in approximately 83% of women with a breast cancer up to 3 cm in size 
(4). Several retrospective studies have shown BCT to be oncologically at least 
equivalent to mastectomy, if not better (12–14). Mastectomy, however, is still 
indicated for larger or inflammatory tumours, in tumour multifocality, as a result 
of patient choice, or in case of an unfavourably high ratio of tumour volume to 
breast volume, and is registered as the final surgical intervention in up to 40% of 
cases in Sweden with some regional differences (4). 
In axillary surgery, there has been a major paradigm shift from viewing it as a 
therapeutic procedure to it being a predominantly diagnostic measure. Sentinel node 
biopsy (SNB) has in many situations replaced the more extensive axillary lymph 
node dissection (ALND), removing 10 lymph nodes or more. The sentinel node, 
introduced in breast cancer surgery in 1994 by Giuliano et al and Krag et al (15,16), 
is the first node that drains the tumour bed and is thought to reliably represent 
the status of the remaining axilla. Long-term follow-up studies confirm that SNB 
alone is safe as a staging method in patients with clinically node- negative breast 
cancer, implying that an ALND can be omitted in case of a negative SNB without 
any impact on axillary recurrence rates (16–18). The use of a SNB instead of an 
ALND leads to decreased arm morbidity since fewer lymph nodes are removed 
(19,20). With improved systemic therapies and decreasing recurrence rates, the need 
for ALND has been questioned even after a positive SNB: The ACOSOG Z0011 
and IBCSG 23-01 trials showed no difference in survival or axillary recurrence 
rate regardless of whether an ALND was performed or not (21,22). Only breast-
conserving surgery was included and thus, data on mastectomy and omission of 
ALND are lacking (23). Likewise, it has been shown that axillary radiotherapy can 
safely replace ALND, but even here, mastectomy patients are under-represented 
(24). An ongoing Swedish randomized trial (SENOMAC) includes 3500 patients 
in several European countries in order to assess the need of ALND in SN-positive 
cases, including those operated with a mastectomy (25).
31.1.2 Chemotherapy
Chemotherapy has been used as breast cancer treatment since about 1960; the first 
chemotherapy showing a survival benefit was a combination of cyclophosphamide, 
methotrexate and fluorouracil (CMF) (26–28). The second generation of chemo-
therapy, containing the anthracyclines doxyrubicin and epirubicin, resulted in further 
survival improvements when used in combination with CMF. A meta-analysis by 
the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) assessing data 
of 100 000 women showed a significant decrease in 10-year breast cancer  mortality 
compared to no cytotoxic treatment (21.5% vs. 27.6%, RR 0.76 [0.68–0.84]) (27). 
Furthermore, anthracycline-based regimes yield a larger decrease in 10-year breast 
cancer mortality than CMF (24.1% vs. 20.0%, RR 0.80 [0.72–0.88]), and the combi-
nation of 5-fluorouracil, epirubicin and cyclophosphamide reduced local recurrence 
rates by about 16% and mortality by 21% (27). Later, the addition of taxanes to 
anthracycline-based regimes further improved 5-year breast cancer mortality from 
11.5% to 10.1% (RR 0.88 [0.81–0.95]) (29). Chemotherapy is most commonly 
given as adjuvant (postoperative) treatment (ACT), but neoadjuvant (preoperative) 
treatment (NACT) is an increasingly used option. NACT was initially used only 
in large inoperable or inflammatory breast cancer but today even tumours as small 
as 2 cm but with aggressive tumour biology, such as HER2-positive and triple-
negative cancers, are considered for NACT. NACT has the potential advantage 
to be tailored according to the individual tumour response monitored in real time, 
and opens up possibilities for accelerated drug development and approval. In a 
meta-analysis by the EBCTCG, assessing data from 4756 women with early breast 
cancer from ten randomized trials, NACT was shown to achieve a 15-year breast 
cancer mortality equal to ACT (34.4% vs 33.7%; 1.06 [0.95–1.18]), but resulted 
in a higher frequency of BCT (64% vs. 49%) as well as a higher local recurrence 
rate (30). In Sweden, 11.2% of all breast cancer was treated with NACT in 2017 
(4). General indications for chemotherapy are high grade and/or high proliferation, 
triple-negative or HER2-positive subtypes, lymph node positivity and young age. 
Chemotherapy, whether given pre- or postoperatively, has significant side effects, 
and biomarkers or genetic profiling predicting response may give us a possibility 
to customize chemotherapy to avoid overtreatment. 
1.1.3 Endocrine therapy
The vast majority of breast cancers (about 80%) have receptors for oestrogen (ER), 
i.e. they are oestrogen sensitive. Either by blocking the receptors or by lowering 
circulating hormone levels, adjuvant endocrine therapy reduces the risk of recur-
rence and even has a prophylactic effect on the contralateral breast. The first endo-
crine drug, Tamoxifen, is a selective oestrogen receptor modulator blocking ER by 
competing with oestrogen (31). Five years of treatment with Tamoxifen reduces 
recurrence rates by nearly 50% (RR 0.53 during the first four years and RR 0.68 
4during years 5–9) and breast cancer-specific mortality by one third during the first 
15 years after starting treatment (RR 0.71 during years 0–4, 0.66 during years 5–9, 
and 0.68 during years 10–14) (32). Aromatase inhibitors (AIs) such as anastrozole 
are non-steroidal inhibitors of the aromatase enzyme, resulting in a decreased con-
version of precursor stages to oestrogen. AIs are commonly indicated in medium 
to high-risk breast cancer in postmenopausal women, and further decrease both 
10-year recurrence rates and 10-year mortality (RR 0.85, p<0.01) when compared 
with Tamoxifen (33). A publication from EBCTCG in 2017 showed that after five 
years of adjuvant endocrine therapy, breast cancer recurrences continue to occur 
throughout a follow-up period of 5 to 20 years. The risk of late distant recurrence 
was strongly correlated with larger tumour size and more advanced axillary status, 
and accordingly, prolonged endocrine treatment for 10-15 years is recommended 
in selected risk groups today (34). 
1.1.4 Targeted therapy
Human epidermal growth factor receptor 2 (HER2) is a tyrosine kinase receptor 
located on the cell surface. The HER2 gene is expressed in about 15-20% of all 
breast cancers, and is associated with more aggressive tumour biology and poor 
prognosis. It is, however, also a predictive biomarker for therapeutic response 
(35): trastuzumab is a monoclonal antibody binding to the HER2 receptor, thereby 
inhibiting cell proliferation. Together with chemotherapy, trastuzumab leads to 
a 34% relative improvement in overall survival in HER2-positive breast cancer 
patients (HR 0.66; [0.57-0.77]) (36). In the neoadjuvant setting, a “double blockade” 
using the complementary HER2 antibodies trastuzumab and pertuzumab results 
in a significantly higher rate of pathological complete response and disease-free 
survival (37). The introduction of trastuzumab as an addition to chemotherapy in 
the treatment of HER2-positive breast cancer significantly improved prognosis 
in this specific subtype. 
1.1.5 Radiotherapy
While breast cancer surgery intends to remove macroscopic disease, the rationale 
behind radiotherapy (RT) to the breast is that it can destroy residual microscopic 
(i.e., occult) tumour cells left in the surgical field and thus eliminate undetected 
multifocal lesions (38). Postoperative RT has shown to decrease local recurrence 
rates as well as improve patient survival both after BCS (39) and mastectomy in 
node-positive disease (40). Radiotherapy may be targeting the remaining breast 
tissue after BCS or the chest wall after mastectomy (local RT), respectively, and 
regional lymph nodes. Swedish guidelines recommend adjuvant RT to the breast 
after BCS in most cases and to the chest wall after mastectomy if tumour size 
exceeds 5 cm or if extensive multifocality was present. Swedish data published 
5in 2018, however, suggest a low-risk BCS group in which postoperative RT to 
the breast can be safely omitted (41). Regional RT is indicated in the case of 
node-positive disease (macrometastases) but international guidelines diverge 
regarding the group of women with 1-3 lymph node metastases and a completion 
ALND performed. In cases with only micrometastases in the SNB, no regional 
radiotherapy is indicated and in cases with only one macrometastasis, regional RT 
can be omitted if the tumour biology is favourable (42). Since RT has known side 
effects such as increased cardiac mortality and risk of other malignancies such 
as lung cancer and esophageal cancer (43), predictive biomarkers of response to 
radiotherapy are being evaluated to avoid overtreatment regarding RT (44,45).
1.2. Breast reconstruction
Mastectomy, especially in younger women, has negative psychological effects 
with reduced self-esteem, changed body image and sexual problems (46). A 
 reconstruction of the breast, using implants, autologous tissue or a combina-
tion of both, can improve body image and quality of life (47). Previously, breast 
reconstruction was mostly performed as a delayed procedure (DBR) but today, 
immediate breast reconstruction (IBR) is gaining popularity (48,49). IBR is per-
formed at the same time as the mastectomy, which allows for skin-sparing or 
nipple-sparing strategies.
1.2.1 Immediate breast reconstruction
In Sweden, an immediate breast reconstruction (IBR) is predominantly implant 
based. After a mastectomy, the implant can be either placed in a fully subpectoral 
pocket (often assisted laterally by the serratus fascia) or in the prepectoral space; 
in addition, a combination can be chosen, replacing muscle coverage at the inferior 
pole with a mesh or acellular dermal matrix. A permanent implant can be used 
as a one-stage procedure in women with smaller breast volume, while a tissue 
expander is commonly used in women with larger breast volume or if skin flaps 
have appeared compromised during surgery. The use of expander devices often 
implies a later revision surgery when the expander is changed to a permanent 
implant (two-stage procedure). 
The Swedish National Breast Cancer Register (NKBC) has documented an increase 
in national IBR rates up to 14% in 2018 (4), which are still low in comparison 
with many other countries (50–52). There are regional differences with 31% in 
Stockholm and 11% in the Southern and 9% in the West region which are difficult 
to explain by geographical conditions, infrastructure and variations in severity of 
the disease (4).
61.2.2 Delayed breast reconstruction
In DBR, it is possible to use either implants or autologous tissue, or a combina-
tion of both. The Latissimus Dorsi (LD) and Deep Inferior Epigastric Perforator 
(DIEP) flaps are the most common flap-based reconstructions, but fat transplan-
tation is another popular autologous option. The DIEP flap is a free flap from the 
abdomen transferred to the mastectomy site and was introduced in 1994 (53). 
Another option is delayed-immediate breast reconstruction which could be used 
in cases with a risk of radiotherapy after mastectomy. This is a two-stage proce-
dure with first (stage I) a skin-sparing mastectomy with insertion of an implant, 
and in those patient who did not get radiotherapy (stage II) underwent immediate 
breast reconstruction and those who get radiotherapy underwent later (stage II) a 
standard delayed reconstruction (54).
1.3 Predictors affecting the choice of surgical treatment
The choice of surgical intervention in breast cancer is mainly based on patient 
and tumour characteristics, as well as surgeon skills and patient preferences, even 
though there are further predictors that may affect surgical strategies. 
1.3.1 Tumour and patient characteristics
In preoperative counselling it is important to remember that the full picture of 
the disease is not yet available, which is especially true for lymph node status 
in clinical lymph node negativity. The ideal preconditions for BCS would be a 
relatively small tumour (<3cm), but even large tumours can be safely excised if 
breast volume and shape allow for oncoplastic volume displacement. Alternatively, 
volume replacement or partial reconstruction can broaden the indications for BCS, 
making use of tissues adjacent to the ipsilateral breast moved into the resection 
cavity as a pedicled flap (perforator flap). For IBR – if a mastectomy is either 
recommended or desired – several risk factors have to be ruled out, and thorough 
information should be given on the pros and cons of IBR versus DBR versus no 
breast reconstruction. 
1.3.2 Preoperative information and involvement in the surgical 
decision-making process
The quality of the preoperative information communicated by the surgeon and the 
breast care team and the discussion of the different treatment options during the 
decision-making process preceding the scheduling of a surgical procedure may differ 
considerably and have a significant impact on patient decisions and post operative 
regret (55–57). A higher level of participation in the decision-making process leads 
to an increased post-decision quality of life and higher satisfaction (58). 
71.3.3 Socioeconomic factors
The association between socioeconomic factors and the stage of the breast cancer 
at diagnosis, as well as the association between socioeconomic factors and surgical 
treatment choices are well documented, where ethnicity, income and education all 
play a significant role (59–61). Studies investigating how socioeconomic factors 
are associated with patient-reported preoperative information regarding surgical 
alternatives, however, are lacking (62,63), even though low satisfaction with infor-
mation prior to breast cancer surgery is associated with an increased likelihood of 
experiencing anxiety and postoperative regret (57,64).
Alderman et al showed that only 33% of women under the age of 80 years under-
going breast cancer surgery had preoperatively discussed breast reconstruction: 
surgeons were significantly more likely to have this discussion with younger, 
more educated patients with larger tumours (55). In another U.S. study, received 
information on IBR prior to surgery was affected by ethnicity and education, but 
data were based on retrospective chart review (65). 
1.4 The effects of radiotherapy on implant-based 
reconstruction
Radiotherapy (RT) affects the choice and planning of any reconstruction due to its 
effect on the surrounding tissues such as underlying muscle, skin and subcutane-
ous fat. RT effects involve chronic inflammatory changes, tissue remodelling and 
fibrosis (66). One well-known complication after implant-based IBR is capsular 
contracture, associated with pain, impaired cosmetic outcome and psychological 
symptoms (67). The risk of surgical complications is 4.2 times higher in patients 
receiving RT before or after implant-based breast reconstruction in a meta-analysis 
of 1105 patients (68). In addition, a higher risk for wound complications and infec-
tion is seen after later ipsilateral adjustment surgery because of the negative affect 
of RT on wound healing and tissue repair (66). With about 11-37% reconstruction 
failure in patients with implants and PMRT, the adverse effect of radiotherapy 
is well documented (69,70). It has been debated whether IBR is indicated in the 
face of PMRT, but it is now internationally agreed that PMRT poses no contrain-
dication to IBR in the well-informed patient (71). In a publication from our own 
group, 77.7% of women receiving PMRT after IBR would still recommend IBR 
to other women in their situation despite an implant failure rate of 15% (70). In 
this publication, however, implant failure included both implant removal due to 
surgical complications and due to the patient’s desire to convert an implant-based 
IBR to an autologous re-reconstruction.
81.4.1 Implant exchange
Even though most tissue expanders can be left in situ for any amount of time without 
the necessity of an implant exchange, they are commonly replaced with a permanent 
implant 6-12 months after completion of PMRT. The optimal timing of the expander-
implant exchange has been widely discussed (72). Hypothetically, early irradiation 
effects need to settle before attempting any implant adjustment surgery (73–75). Other 
factors to take into consideration that may affect the outcome after implant exchange 
surgery are implant type, complications and lifestyle risk factors. An important clini-
cal question is to what degree the timing of expander-implant exchange in relation 
to PMRT increases the risk of surgical complications, since unnecessary exposure 
to significant risks such as implant removal must be carefully considered (74,75). 
1.4.2 Capsular contracture
In case of severe capsular contracture, revision surgery commonly involves incision 
or removal of the capsule (capsulotomy or capsulectomy) with an exchange of the 
implant or a conversion to a fully or partly autologous re-reconstruction. Potential 
explanations of the underlying aetiology of radiation-induced fibrosis by e.g. genetic 
variation are as yet not conclusive (76). Variations in gene expression patterns in 
irradiated recipient vessels from autologous flap reconstructions (77), as well as in 
adipose tissue from the irradiated breast (78) have previously been described by our 
group, but to our knowledge there is no study that has investigated gene expression 
patterns in irradiated breast capsular tissue. In order to minimize the capsular con-
tracture in the setting of aesthetic breast augmentation, several strategies have been 
proposed to reduce capsular inflammation (79). Capsular contracture after  aesthetic 
breast augmentation, in the absence of irradiation, is associated with inflammatory 
cell recruitment together with an increased expression of toll-like receptor 4 (TLR4) 
(80) and cysteine leukotriene receptor 2 (CysLTR-2) (81) in fibroblasts within the 
capsular tissue. Further investigation of the basic components in the innate and 
adaptive immune responses, with focus on specific T and B cells, would be of 
great interest. Leukotriene inhibitors have been suggested as a prophylactic treat-
ment with the goal of reducing the risk of capsular contracture in aesthetic surgery 
(82). Furthermore, interleukin 8 (IL8) and metallopeptidase 4 (TIMP4) have been 
suggested as potential key diagnostic and prognostic biomarkers (83). While most 
studies have been conducted in purely aesthetic surgery, PMRT after reconstruction 
can further enhance inflammatory cell recruitment and fibrosis. The Wnt signalling 
pathway, previously known for pathogenesis of radiation-induced fibro-proliferation 
as showed by Lipa et al, may play an important part in capsular contracture after 
breast reconstruction using expander implants followed by PMRT (84). The study, 
however, was extremely small and did not evaluate gene expression patterns. Due 
to the incomplete understanding of the pathogenesis of radiation-induced inflam-
mation and the development of capsular contracture in breast cancer patient led us 
to investigate differences in gene expression patterns and immune cell composition 
in irradiated versus non-irradiated breast capsular tissue.
92 AIMS OF THE THESIS
The specific aims were:
I. To analyse the causes of regional variations in IBR rates in Sweden through 
consideration of tumour data together with patient-reported experiences of 
information and decision-making before surgery,
II. To investigate potential associations between socioeconomic factors and IBR 
rates, as well as patient-reported preoperative information and involvement 
in the surgical decision-making process,
III. To explore associations between socioeconomic factors and breast conser-
vation rates, together with patient-reported preoperative information and 
involvement in the surgical decision-making process, 
IV. To assess how the timing of implant revision surgery after the completion 
of PMRT as well as other clinical risk factors affect surgical complications 
resulting in implant failure, 
V. To identify differences in gene expression patterns and immune cell com-
position in irradiated versus non-irradiated breast capsular tissue to better 
understand the underlying biology of radiation-induced capsular contracture.
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3 METHODS
3.1 Patients and methods
3.1.1 Study I-III 
The first three studies were based on a retrospective cohort design, including the 
complete annual cohort of women registered for breast surgery due to a primary 
breast cancer in Sweden in 2013. In study I and II, the subgroup of women with 
a mastectomy as the final surgical intervention were selected, while women with 
any type of surgical treatment were included in study III. In bilateral cases, one 
breast was randomly selected. Data on patient and tumour characteristics as well 
as received treatment were extracted from the Swedish National Breast Cancer 
Register, which includes 99–100% of all new breast cancer patients (85,86). No data 
on DBR was available since there is no national register providing this information.
A postal questionnaire asking for patients’ experiences of preoperative information 
about their surgical and reconstructive options as well as their perceived involve-
ment in the surgical decision-making process were dispatched in spring 2015. The 
questionnaire also covered hereditary risks and asked for the patients’ own view 
on requesting a breast reconstruction or not. Questions regarding any preopera-
tive discussion of breast-conserving options as an alternative to mastectomy were 
only used in study III. Postal addresses were retrieved from the tax authority via 
personal identification numbers. Non-responders were sent a reminder after three 
months, and data collection was closed on October 30, 2015. Questionnaire data 
were then linked to individual patients’ tumour data. A separate questionnaire was 
sent to all breast surgeons registered as members of the Swedish Association of 
Breast Surgery, and included questions on reconstructive skills and experience as 
well as local availability of reconstructive surgery services. The questionnaire was 
anonymous and could not be traced to any individuals, hospitals or departments.
In preparation for study II and III, which were conceived based on the results of 
study I, data from the Swedish National Breast Cancer Registry were updated 
by a new data extraction in 2016; therefore, cases numbers were completed by 
late incoming registrations which increased the cohort size analysed in  studies 
II and III. Socioeconomic background data were received from the Swedish 
Total Population Registry (TPR), the Register on Income and Taxes (IoT), the 
Longitudinal Integration Database for Health Insurance and Labour Market Studies 
(LISA), the Swedish Register of Education, and the Swedish Occupational Register, 
all maintained by the Central Bureau of Statistics Sweden, and linked with NKBC 
and questionnaire data. Personal data were de-identified before receipt and analysis. 
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The Ethical Review Authority at Karolinska Institutet approved study I in 2014 
(2014/2106-31/1) and study II and III, including amendments in order to update 
the original database, in 2016 (2016/373-32, 2016/805-32, 2016/2202-32).
3.1.2 Study IV
A complete retrospective cohort of women who had undergone implant exchange 
and/or capsulotomy or capsulectomy at Karolinska University Hospital between 
2005 and 2015 was identified through individual codes for performed surgery reg-
istered according to the Classification of Health Interventions. Incorrectly coded 
or purely prophylactic cases, secondary breast reconstructions and other types of 
revisions not involving intrusion into the implant cavity were excluded. Thus, 
remaining patients all had a previous therapeutic mastectomy and an implant-
based IBR. Any implant failures occurring before a first surgical revision, i.e. 
in the postoperative period following the primary surgery, were excluded from 
analysis; likewise, if implants were removed due to a patient’s own preference 
or in the context of a conversion to an autologous breast re-reconstruction, these 
cases were also excluded. 
Information on tumour characteristics, surgical and oncological treatment, lifestyle 
risk factors and comorbidity (smoking, BMI, hypertension, immunosuppressive 
medications) were collected through individual medical chart review and entered 
into the electronical Stockholm Breast Reconstructive Database. The main out-
come was implant failure due to postoperative complications associated with 
revision surgery after IBR. Time was calculated from the last day of RT to the 
date of revision surgery. In case of multiple revision surgeries, each intervention 
counted as one separate case, with the time corresponding to each individual date 
of revision surgery.
The original study was approved by the Ethical Review Authority at Karolinska 
Institutet, Stockholm, in 2015 (2015/1183-31/4).
3.1.3 Study V
3.1.3.1 Human tissue samples
A total of 44 patients (46 breasts), who underwent an implant exchange or a con-
version to an autologous reconstruction after an IBR, were included after signing 
an informed consent. Irradiated (n=23) and non-irradiated (n=23) 10 mm x 10 mm 
biopsies were collected from the lateral lower quadrant capsule at two institutions 
in Stockholm. Each biopsy was divided into to two parts, one stored in forma-
lin for immunohistochemistry and Allprotect Tissue Reagent® (Qiagen, Hilden, 
Germany) and kept at –80 °C for RNA purification.
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The Ethical Review Authority at Karolinska Institutet approved this study in 2017 
(2017/1504-31/2) and all samples were registered and stored in the Stockholm 
Medical Biobank (nr 914). 
3.1.3.2 Extraction of RNA 
Extraction of RNA was performed using The RNeasy Lipid Tissue kit ® (Qiagen) 
according to the protocol of the manufacturer. Microcapillary electrophoresis 
was performed to evaluate RNA quality, by using an Agilent Bioanalyzer® 
with RNA 6000 Pico Kit and Agilent 2200 TapeStation with RNA ScreenTape 
(Agilent, Santa Clara, California, USA). While ultraviolet spectrophotometry 
was performed to measure the RNA quantity, by using NanoDrop® ND-1000 
UV-Vis Spectrophotometer (Thermo Scientific, Waltham, Massachusetts, USA). 
The whole-transcriptome expression was retrieved by processing 50ng of each 
RNA sample, using GeneChip® WT Pico Reagent Kit (Affymetrix, Santa Clara, 
California, USA), which produces amplified and biotinylated sense-strand DNA 
targets for hybridization to Clariom D arrays.
3.1.3.3 Profiling of gene expression
The gene expression was assessed by microarrays analysis, Affymetrix® Clariom 
D human oligonucleotide microarrays (Affymetrix, Santa Clara, California, 
USA), and carried out by the core facility for Bioinformatics and Expression 
Analysis at Karolinska Institutet. The scanning from the files were processed in 
Transcriptome Analysis Console using the Signal Space Transformation-Robust 
Multi-Chip Analysis method. The transcripts registered as encoded genes accord-
ing to The National Center for Biotechnology Information (NCBI)’s database for 
gene-specific information, Entrez Gene, http://www.ncbi.nlm.nih.gov/gene , were 
extracted if present in at least one of the irradiate or non-irradiated groups. The 
most differentially expressed genes between the irradiated and the non-irradiated 
samples were identified.
Enrichment testing was performed in order to identify different levels of gene sets 
and pathways associated to RT-responsive genes, by using The Molecular Signatures 
Database (MSigDB, https://www.gsea-msigdb.org/gsea/msigdb/index.jsp).
3.1.3.4 Evaluation of immune cells
To assess the relative levels of specific immune cell types within the complex gene 
expression mixture, based on the RNA expression patterns, the analytical platform 
CIBERSORT (https://cibersort.stanford.edu/) was used. Immune cell type differ-
ences between the irradiated and the non-irradiate groups were also compared.
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3.1.3.5 Immunohistochemistry
The formalin-fixed tissue samples were embedded in paraffin after being pro-
cessed in an automated tissue processing machine (VIP 3000, Miles Scientific). 
The 4-μm-thick sections were then mounted on glass slides (Superfrost+, Thermo 
Scientific) and heated for 3 hours at 56°C. Each section de-paraffinized in xylene 
and rehydrated in alcohol before a heat-induced epitope retrieval was performed 
using a Decloaking Chamber (Biocare Medical) set for 5 min at 110°C in Citrate 
buffer pH 6 (Sigma C-9999). To stop the endogenous peroxidase, a 30-minute 
incubation in 0.15 % hydrogen peroxidase was performed at room temperature, 
followed by a 30-minute blocking step using 1% bovine serum albumin (BSA). 
Primary antibodies were diluted 1/2000 (CD3), 1/600 (CD20), 1/1000 (CD68), in 
1% BSA and incubacted at +4°C overnight in a humid chamber. The secondary 
biotinylated antibody (Vector Laboratories) was diluted 1/200 and incubated for 
30 min at room temperature, followed by 30 min incubation with avidin-biotin 
enzyme complex (Vectastain) ELITE ABC kit (HRP, Vector Laboratories). The 
peroxidase substrate DAB (ImmPACT DAB SK-4105, Vector Laboratories) was 
used for 3 minutes for visualization. Each section was then counterstained in Mayer's 
hematoxylin for 1 min followed by dehydration with graded alcohols, xylene and 
cover slipped with Mountex. Alongside the capsular surface, three high power 
fields (x20) were chosen with a depth of 200 µm below the surface. Staining of 
capsular biopsies for CD3+, CD20+ and CD68+ were performed. CD3+ is a T cell 
co-receptor and CD68+ is highly expressed in macrophages. CD20+ is expressed 
on the surface of B cells, which is a essential for the adaptive part of the immune 
response. Two blinded evaluators independently counted the numbers of CD3-, 
CD20- and CD68-positive cells.
3.2 Statistical analysis
As an overall standard, the distribution of data was tested for normality before 
further analysis, and parametric or non-parametric tests used accordingly. In study 
I-IV, categorical data were presented as case numbers per group with their per-
centages, and groups compared by the Chi Square or Fisher’s exact test. When 
presenting continuous variables, median values and their range were used. For 
comparisons between groups, the Mann-Whitney (two groups) or the Kruskal-
Wallis test (more than two groups) was employed. 
Uni- and multivariable logistic regression analyses were performed when testing 
associations of potential factors with a binary outcome. Results are presented as 
odds ratios (OR) with their respective 95% confidence intervals (Cl). SPSS® 
 version 24 (IBM, Armonk, New York, USA) was used to perform all analyses 
with statistical significance set at the 0.05 level. 
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3.2.1 Study I-III
In study I and II, the original mastectomy cohort was divided into two groups: 
women with and those without an IBR. The NKBC cT status “cT0” (“no obvious 
tumour”) was categorized as cT1 since cT0 is normally based on palpation only 
instead of radiological findings, as opposed to cTis (in situ only). In order to  identify 
patients with a low likelihood of PMRT according to preoperative parameters, 
clinically node-negative patients aged 65 years or less with small tumours (cT1), 
in situ disease only (cTis) or no signs of a primary tumour (cT0) were selectively 
defined as “low tumour burden” group. A separate analysis was also performed 
to compare responders with non-responders (study II).
In study III, the original cohort included all types of breast surgery, and two groups 
were created for comparison: patients treated with breast-conserving surgery and 
those treated with mastectomy (with or without IBR). Since IBR patients were 
found to differ from mastectomy patients without IBR in several aspects, analy-
sis was first conducted on all mastectomy patients, i.e. including those with an 
IBR, and then completed with a second analysis excluding IBR patients. For the 
specific purposes of study III, the following questions were selected from the 
patient questionnaire: “Did your surgeon discuss the option of breast-conserving 
surgery?” (Yes/Yes, partly/No), “Who took the decision to choose mastectomy?” 
(My choice, Surgeon’s choice, Both), and “Did you feel involved in the decision-
making process to choose mastectomy?” (Yes/Yes, partly/No). The alternatives 
“Yes” and “Yes, partly” as well as “My choice” and “Both” were then merged 
for the statistical analysis. In a separate analysis, questionnaire data from patients 
with invasive tumours were compared between two groups: patients with smaller, 
clinically node-negative tumours (cT1), likely to be technically suitable for BCT, 
and patients with clinically larger tumours (cT2-cT4). 
Univariable binary logistic regression analysis was performed to study the associa-
tion of tumour/patient characteristics and information/involvement with perfor-
mance of IBR versus no IBR in study I. In study II, the binary outcome was the 
same as well as all included variables, but socioeconomic factors were added to 
the analysis. For study III, the binary outcome was the performance of BCS versus 
mastectomy (with or without IBR). Questionnaire data on information/involvement 
could not be included in the regression analysis in study III, since women with 
BCS had not participated in the survey. In a subsequent step, all factors selected 
for univariable analysis were also entered into a multivariable model.
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3.2.2 Study IV
After descriptive analysis, data were entered into a univariable binary logistic regres-
sion with implant failure versus no implant failure as the endpoint. Performing a 
multivariable regression was not deemed appropriate due to the limited number of 
events. In order to reflect the situation in the clinical reality and thus the need of 
data facilitating preoperative counselling, the implant failure rate was calculated 
per revision surgery and not per breast or individual.
3.2.3 Study V
The differences in expression levels in irradiated and non-irradiated samples were 
calculated in groups using moderated t-tests as implemented in the BioConductor 
Limma kit. Only genes expressed in either of the treatment groups by using 
Transcriptome Analysis Console while also containing protein-coding exons 
and being listed in Extrex Gene were included for further analysis. The selected 
genes for enrichment testing had a p-value <0.05. The Reactome and ontology 
 biological gene sets were considered significantly overrepresented with a corrected 
a P-value<0.05 and False Discovery Rate <5%. 
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4 RESULTS
4.1 Study I-III
In study I, 2929 women who had received a mastectomy as the final surgical inter-
vention in 2013 were identified through the NKBC (Table 1 in study I). In 412 
women (13.8%), breast conservation was primarily attempted and the mastectomy 
performed at a second session. 
In study II-III, data on 7735 women were received from NKBC, of whom 4604 
(59.5%) were operated with BCS and 3131 (40.5%) with mastectomy (Table 1 in 
study III). Of the latter group, 267 women (8.5%) had received an IBR (Table 2 in 
study II). For 78 women with bilateral disease, one side was selected at random. 
4.1.1 Regional differences in treatment, tumour and patient 
characteristics (Study I-III)
Pre- and postoperative patient and tumour characteristics by healthcare regions are 
presented in Table 1 in study I for the mastectomy cohort (with or without IBR) 
and in Table 3 in study III for all women who underwent breast cancer surgery. 
The IBR rate was highest in the Stockholm/Gotland region with 25.6% and lowest 
in the West region with 3.0% (study I) Likewise, BCS rates varied from 66.1% 
in Stockholm/Gotland to 50.7% in the Southeast region (study III). Even though 
tumour characteristics differed between regions, no explanatory patterns for BCS 
or IBR variations could be discerned.
Looking for factors that could explain the regional differences in IBR rates, the 
association with planned postoperative radiotherapy and age at surgery were specifi-
cally analysed (study I). There were significant differences in preoperative tumour 
stage, rates of neoadjuvant treatment and the frequency of planned postoperative 
radiotherapy (as discussed at the postoperative multidisciplinary team meeting) in 
different regions, but these differences could not explain variations in IBR rates. 
The Stockholm/Gotland region with the highest IBR rate also had the highest rate 
of neoadjuvant therapy and highest percentage of more advanced tumours (cT3-4), 
whereas the region with the lowest IBR rate (West) had the highest percentage of 
smaller tumours and the lowest rate of both neoadjuvant therapy and postoperative 
radiotherapy. Median patient age did not differ between regions. 
Of all women without a reconstruction, 657 out of 1947 (33.7%) reported that they 
themselves did not wish a breast reconstruction, and 155 (8.0%) wanted to wait 
with breast reconstruction until later. Since a common argument against offer-
ing IBR in several Swedish regions is planned RT, a previously described “low 
tumour burden” group (see Methods) was selected, consisting only of women 
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with a low likelihood of adjuvant RT after IBR. Even in this subgroup, patient 
participation in treatment decision and perceived preoperative information still 
varied extensively between Swedish healthcare regions, contradicting the above 
assumption that younger women with no risk factors for receiving postoperative 
RT would be sufficiently informed about IBR, see Table 1 below (corresponding 
to Table 4 in Study I). Patient information about delayed breast reconstruction 
(DBR) was generally higher, even though it also varied significantly in the low 
tumour burden group. 
Table 1. Preoperative patient-reported perception of information about breast recon-
struction and involvement in treatment decision, in each Swedish healthcare region.
4.1.2 Socioeconomic factors (Study II and III)
When comparing women who had an IBR with those who had a mastectomy only 
within the mastectomy cohort (studies I and II), the first were more likely to be in 
a partnership or married (60.7%), had most often a Swedish background (82.8%) 
and the highest level of education (35.6 %), and were most often employed as 
clerks or civil servants (54.7%) with a high income per household (55.1%; Table 3 
in study II). In table 4 in study II, the six Swedish healthcare regions are com-
pared: socioeconomic background, tumour data and IBR rates differed signifi-
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cantly among women treated with mastectomy. The region of Stockholm/Gotland, 
with the highest IBR rate of 25.6%, had the lowest rate of small tumours and the 
youngest age at surgery, but also the highest rate of non-Swedish born women, a 
high level of education, fewest unemployed or retired individuals, and the largest 
high-income group. 
When extending the cohort to all types of breast surgery (study III), women receiv-
ing BCS were more often in a partnership or married (58.1%) and had a middle 
or high income (35.3% and 35.4%, respectively) than patients with a mastectomy 
with or without IBR. In table 3 in study III, the regional distributions of all vari-
ables and the significant variation of BCS rates are reflected. Even though tumour 
characteristics differed between regions, no explanatory patterns for BCS variations 
could be discerned. As illustrated, Stockholm/Gotland clearly differed from the 
other regions in all socioeconomic factors. Since only those women operated by 
mastectomy, not those treated with BCS, had been sent a questionnaire regarding 
perceived patient information and involvement in the treatment decision, ques-
tionnaire results were selectively analysed. Women who felt that the mastectomy 
decision was their own choice were older (p<0.001), had smaller tumours (cT1, 
p<0.001) and fewer axillary metastases (p<0.001), lived more often in the North 
region (p=0.033) and were less often registered as working as labourers (p < 0.001). 
Women who did not feel the choice was theirs but still felt involved in the deci-
sion were significantly older than those who did not (p=0.034), and had smaller 
tumours without axillary metastases (p=0.001). Women who reported that BCS 
had been discussed as an alternative to mastectomy did not differ in age or region 
of residence, but had smaller tumours without axillary metastases (p<0.001), lived 
more often in a partnership (p<0.001), had an employment (p=0.031) and were more 
often not born in Sweden (p=0.035). They also had a tendency to have a higher 
income but this did not reach statistical significance (p=0.051). When selectively 
analysing women with clinically smaller tumours (cT1) who should have been 
technically feasible candidates for BCS, rates of preoperative information on BCS 
and perceived involvement were surprisingly low and varied significantly in differ-
ent health care regions, see Table 2 below (corresponding to Table 5 in study III). 
Overall, lower socioeconomic status was associated with larger clinical tumour 
size (p<0.001 for all variables) as was being born outside Europe (median inva-
sive tumour size 19 mm versus 16 mm, p=0.002). In the latter subgroup, axillary 
lymph nodes were significantly more often clinically positive than in women born 
in Sweden and Europe (16% versus 9.8% and 11.8%, respectively; p < 0.001). Of 
women born in Sweden and women born in Europe, 14.1% and 12.7% perceived 
the decision of mastectomy as their own or theirs together with the surgeon, while 
the corresponding figure was only 9% for women born outside Europe (p=0.002). 
Excluding IBR patients from the mastectomy group, no difference in perceived 
involvement in the mastectomy decision was seen between different regions of 
origin (p=0.162), while all other factors diverged even more strongly.
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Table 2. Patient-reported preoperative information about breast-conserving  surgery 
and perceived involvement in the surgical decision among women treated with 
 mastectomy (with or without IBR) in each Swedish healthcare region.
4.1.3 Socioeconomic differences in questionnaire responders 
versus non-responders
The response rate to the postal questionnaire was 76.3% (2217 of 2906) after one 
postal reminder. Of 2217 responders, data for 46 individuals were lost on linkage 
to socioeconomic data. In study II, a comparison between 2171 responders and 
960 non-responders showed that the first group comprised younger women with 
more favourable tumour disease, a slightly lower rate of IBR and a higher socio-
economic status (Table 1 in study II).
4.1.4 Education and skill level in reconstructive techniques 
among breast surgeons and availability of in-house plastic 
surgery services
Ninty-one out of 151 breast surgeon (60.3%) registered as members of the Swedish 
Association of Breast Surgery answered the anonymous questionnaire about skill 
level in reconstructive techniques. Five surgeons reported they had either retired 
or stopped working with breast cancer patients, resulting in 86 completed ques-
tionnaires. The majority of responders were senior surgeons with more than five 
years as a consultant (72 of 86; 84%), and with breast surgery representing more 
than 50% of their daily clinical activities (64 of 86; 74%). Eight (9%) reported 
being trained in plastic surgery. Forty-two% (36 out of 86) of the responders could 
perform an IBR independently, and 76% reported IBR availability at their own 
hospital. A large majority (81%) wished to receive more training in oncoplastic 
and reconstructive breast surgery. Median age was 55 (range 34-71) years, and the 
distribution between regional, county and university hospitals was even. 
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The availability of in-house plastic surgery services was reported per hospital 
where patients had been operated. Availability varied between 95.3% (calculated 
per patient) in Stockholm/Gotland and 30.0-57.5 % in other regions. While this 
did not suffice to explain regional differences, it increased the likelihood of being 
informed about IBR options (HR 0.74, 95% CI 0.62 to 0.87). The rate of IBR was 
higher in regional hospitals without a department of plastic surgery but with a 
plastic surgeon available than in university hospitals with an own department of 
plastic surgery (17.2 versus 11.5%; p<0.001). Without any plastic surgery service, 
the IBR rate fell to 3.0%.
4.1.5 Independent predictors of receiving BCS or IBR
Independent predictors for undergoing BCS were a smaller tumour, clinically 
uninvolved lymph nodes, living in the North or the Stockholm/Gotland region, 
a higher education and a higher income, see Table 3 below (corresponding to 
Table 4 in study III). When running multivariable regression analysis excluding 
those women having received an IBR, the oldest together with the youngest age 
group showed the lowest probability to receive BCS, and having the highest level 
of education did no longer act as an independent predictor of BCS (OR 1.18, 95% 
CI 0.98–1.41). Living in the Stockholm/Gotland region resulted in a significantly 
increased likelihood of BCS compared to the reference region North (OR 1.39, 
95% CI 1.10–1.76). 
Younger age, non-invasive disease, no clinically involved lymph nodes and residing 
in the Stockholm/Gotland region were independent predictors of undergoing IBR, 
as well as the availability of in-house plastic surgery services, patient information 
and involvement in decision-making. An important question was if the observed 
regional differences were associated with differences in socioeconomic background. 
To assess this, uni- and multivariable analyses were performed. Socioeconomic 
factors that independently increased the likelihood of having an IBR were living 
in a single household, being employed, and having a higher income, see Table 4 
below (corresponding to Table 5 in study II). To be single appeared to decrease the 
likelihood of IBR in the univariable analyses, but this association reversed when 
adjusted for age, as being single strongly interacted with younger age. Despite 
these adjustments for socioeconomic status, the single most important independent 
predictor remained patient-reported preoperative information about the possibility 
of IBR. Patient-reported involvement in the surgical decision-making process was 
also confirmed as a significant independent factor for IBR.
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Table 3. Univariable and multivariable binary logistic regression analysis of  clinical 
and socioeconomic factors with performance of breast-conserving surgery as 
opposed to mastectomy (with or without IBR) as the binary endpoint.
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Table 4. Univariable and multivariable binary logistic regression analysis of clinical 
and socioeconomic factors, with performance of immediate breast reconstruction as 
opposed to mastectomy without reconstruction as the binary endpoint (mastectomy 
patients only).
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Independent predictive factors for reporting having received preoperative informa-
tion about IBR were having a non-invasive tumour (OR 3.56, 95% CI 2.29-5.55), 
living in the Stockholm/Gotland region (OR 2.64, 95% Cl 1.70-4.11) and being 
born outside Europe (OR 2.83, 95% Cl 1.68-4.77). Negative predictive factors 
were being more than 65 years old (OR 0.43, 95% Cl 0.26-0.71) and having no 
current employment (including retirement) (OR 0.69, 95% Cl 0.49-0.97). The 
small group of 154 women with a non-European background, mostly born in Asia, 
were younger and had a higher educational level than Swedish or European-born 
women, and most of them lived in the Stockholm/Gotland area.
4.2 Study IV
The final cohort consisted of 475 breast cancer patients (542 breasts) in whom 
707 implant revision surgeries had been performed (Figure 1 in study IV). Median 
follow-up time, i.e. time from revision surgery to medical chart review, was 95 
months (range 2-215). For details on patient and tumour characteristics per breast, 
see Table 1 in study IV.
Due to a previous breast cancer treated by breast conservation (N=23) or due to 
lymphoma (N=1), twenty-four breasts (4.4%) had been irradiated between 1 and 
25 years prior to IBR. In a further 223 cases (41.1%), the chest wall had been 
irradiated after mastectomy (PMRT) and IBR, while 288 breasts (53.1%) had 
never been irradiated. In seven cases and eight revision surgeries, information on 
irradiation was missing and these cases were therefore excluded. Due to surgical 
complications, a total of 33 implants (one bilateral case of implant failure) were 
removed, see Figure 1 (corresponding to Figure 1 in study IV). In the group of 
non-irradiated breasts, the implant failure rate was lowest with 2.4% (9 out of 375). 
Corresponding figures were 7.5% (22 out of 293) in the PMRT group and 6.5% 
(2 out of 31; overall p=0.008) in the group with RT given prior to IBR. In most 
cases (76.8%), only one revision surgery had been performed, with a median of 
one revision surgery involving the implant cavity (range 1-5) during follow-up. 
The median time from revision to implant failure was two months (1-153). 
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Figure 1. Flow chart for the creation of the final cohort of cases of implant removal (N=33) 
and no implant (N=509)
Median time from completion of any RT (PMRT or prior to IBR) to revision sur-
gery was 14.5 months (1-338); the cohort was accordingly divided into two groups 
using the median as a cut-off. Among cases of implant failure, 42.1% had revision 
surgery performed less than 14.5 months after RT completion, and 57.9% after 
more than 14.5 months (p=0.633). Thus, no significant impact of timing of revi-
sion surgery could be identified. Please see Table 2 in study IV for radiotherapy 
details per breast. 
In Table 5 (corresponding to Table 3 in study IV), unadjusted risk factors for 
implant failure, calculated per breast, are presented. Known risk factors such as 
current smoking and antidiabetic treatment were confirmed in the present cohort. 
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A significantly increased risk of implant failure after revision surgery was seen in 
patients with an infection after the initial operation, namely mastectomy and IBR. The 
increased risk was seen regardless of whether the previous infection was clinically 
diagnosed or confirmed by bacterial cultures and/or elevated inflammatory markers 
such as the C-reactive protein. This is noteworthy since these infections had obviously 
not resulted in an implant failure during the postoperative period following IBR. 
Table 5. Univariable logistic regression analysis with breast implant failure as the 
endpoint. 
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Both node positivity and axillary node dissection increased the risk of implant 
failure five-fold. Both prior RT and PMRT were a significant risk factor for 
implant failure. However, data on RT fields showed that this increased risk was 
only seen in patients with locoregional radiotherapy and not if it only targeted 
the chest wall. To differ between the effect of locoregional radiotherapy and that 
of axillary surgery, both covariates were entered into the same regression model. 
Interestingly, locoregional radiotherapy lost its significance (OR 2.11, 95% CI 0.85-
5.24) when compared with no radiotherapy, while axillary lymph node dissection 
retained its significant negative effect on the risk of implant removal (OR 2.99, 
95% CI 1.08-8.27).
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4.3 Study V
4.3.1 Human tissue specimens 
A prospective cohort of 44 patients was available for biopsies, with two patients 
having biopsies from both breasts. Biopsies from 25 breasts met the criteria set 
for RNA quality and quantity and were included in gene expression analysis, see 
Figure 2 (corresponding to Figure 1 in study V). From completion of RT to cap-
sular biopsy, median time was 35 (18-304) months. The median radiation dose 
was 50 (46-50) Gy.
Figure 2. Flowchart of the cohort of biopsies.
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4.3.2 RNA Extraction
Of the 25 biopsies selected for gene expression analysis, 13 came from irradiated 
breasts and 12 from non-irradiated breasts, with a RNA integrity number greater 
than 5 and with a quantity of more than 100ng. 
4.3.3 Gene expression
Microarray experiments were conducted at two time points and therefore subjected 
to a batch-control analysis showing a negligible temporal effect, which further 
validated the reproducibility of the experiment. Altogether 3422 transcripts, reg-
istered as encoded genes according to Entrez Gene, were present in at least one 
of the groups. A set of the most differentially expressed transcripts, with a raw 
p-value below 0.05, were selected for enrichment testing (n=227). Gene ontology 
(GO) analysis showed that the selected radiation-responsive genes were mainly 
involved in inflammatory response among the top 21 identified GO biological 
processes (p<0.05; FDR<5%). Both innate and adaptive immune responses were 
represented. The top three GO biological processes identified were humoral immune 
response mediated by immunoglobulins, followed by complement activation and 
B cell-mediated immunity (Table 1 in study V). In the Reactome gene sets analy-
sis, scavenging of heme from plasma, C2 and C4 activators and binding/uptake of 
ligands by scavenger receptors were the most dysregulated (Table 2 in study V). 
4.3.4 Estimating the composition of immune cells
CIBERSORT was used to estimate the immune cell composition of the 25 samples 
and to quantify the relative levels of different cell types in a mixed cell popula-
tion. Macrophages and T-cells were the most common immune cells in the biopsy 
material, see Figure 3 (corresponding to Figure 2 in study V). No significant dif-
ferences between irradiated and non-irradiated samples were seen regarding the 
numbers of macrophages and T-cells, except for γ/δ T cells, which were more 
common in irradiated biopsies (p=0.022).
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Figure 3. Immune cell composition
Macrophages and T-cells were most common. There were no significant  differences 
between the RT- and RT+ groups, except for γ/δ T cells (p=0.022).
4.3.5 Immunohistochemistry
The most relevant cell types according to enrichment testing were analysed with 
cell-specific markers. There were only eight corresponding biopsies with intact 
morphology of the capsular surface and adequate staining quality for cell counting 
out of the 25 biopsies that were included in gene expression analysis. Consentient 
cell counts were obtained by two blinded evaluators. There was a significantly 
higher number of CD68+ cells compared to CD3+ cells (p=0.0062) and CD20+ cells 
(p=0.0025) in the total number of analysed stainings, corresponding to CIBERSORT 
results. No differences were seen between RT+ or RT- biopsies except for CD20+ 
cells that were more commonly seen in the RT+ biopsies (p=0.016), see Figure 4 
(corresponding to Figure 3 in Study V). There was evidence of B-cell infiltration 
in irradiated biopsies only. 
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Figure 4. Results of the immunohistochemistry
Staining of capsular biopsies for T-cells (CD3+), B-cells (CD20+) and macrophages 
(CD68+) revealed that CD68+ cells were significantly more prevalent than CD3+ 
and CD20+ cells (p=0.0062 and p=0.0025 respectively, for RT- and RT+ groups 
combined). Comparison of staining in irradiated and non-irradiated groups iden-
tified differences for CD20+ cells, with a significantly higher frequency in the 
irradiated material (p=0.016). Indeed, B-cell infiltration was only evident in the 
irradiated biopsies.
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5 DISCUSSION
In this PhD thesis we have investigated the causes of variations in BCS and IBR 
rates in the six Swedish healthcare regions, which could not be explained by differ-
ences in tumour characteristics or age distribution. Instead, a significant disparity 
in patient information and involvement in decision-making was found, congruent 
with differences in both BCS and IBR rates. This remained true when selecting 
groups of women without any contraindications against IBR or BCS according 
to available data. Socioeconomic factors were also significantly associated with 
both BCS and IBR rates, but did not eliminate the strong significance of patient 
information and involvement. Since responders to the patient survey differed from 
non-responders, results cannot be generalized; on the other hand, however, the 
observed disparities would have been even more significant with a higher response 
rate since the characteristics of non-responders were much similar to those of 
women not receiving IBR and reporting not being well informed. 
Furthermore, we evaluated the optimal timing and clinical risk factors for com-
plications after implant-related revision surgery following a previous IBR, with 
special regard to PMRT. Even though RT significantly increased the risk of 
implant failure following implant exchange surgery, we could not find any sup-
port of optimal timing of the exchange procedure in relation to PMRT, which is 
potentially due to the fact that a minimum time frame of six months past PMRT 
is regarded gold standard in Stockholm since many years. Interestingly, previous 
axillary lymph node dissection and a history of a previous postoperative infection 
emerged as important risk factors to take into consideration. Finally, we compared 
gene expression levels and immune cell distribution between irradiated and non-
irradiated capsular biopsies, and could observe a sustained innate and adaptive 
immune response. 
In the preoperative meeting between the patient and the responsible breast surgeon 
and the supporting breast care team counselling for the upcoming treatment, there 
are several factors to take into consideration. First of all, tumour characteristics: in 
our study, even though tumour parameters varied between the healthcare regions, 
these factors could not explain regional variations in either BCS or IBR rates as 
they did not follow the same pattern. Since the counselling breast surgeon does 
not know the full extent of the disease at this preoperative meeting, only factors 
commonly available at this time were considered. Tumour characteristics, how-
ever, can already at this time give some hints about appropriate adjuvant  therapies 
such as radiotherapy. Secondly, patient factors: unfortunately, common risk  factors 
associated with inferior IBR outcome, such as smoking and obesity, were not 
available in our early analyses. Likewise, the size and shape of the breast plays 
a major role during preoperative counselling but was not registered in this retro-
spective study. With the help of the patient questionnaire, we could at least assess 
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the most important patient factors, i.e. patient preference, perceived information 
and feeling of being involved in the decision. Thirdly, the breast care team: not 
only the surgeon is responsible for correct information and counselling, but this 
task is shared between the surgeon, the members of the multidiscplinary team 
conference and the breast nurses who commonly have more frequent contact with 
the patient than the surgeon. Even in clinics where plastic surgeons perform or 
assist the IBR, information regarding reconstructive alternatives will typically be 
delivered by the breast surgeon.
Hence, a large part of preoperative patient information – even though shared with 
and supported by breast nurses – lies with the breast surgeon. This raises the ques-
tion whether surgeons and their teams trained in and familiar with reconstructive 
methods are more likely to inform patients about their reconstructive options. The 
fact that rates of preoperative patient information and involvement regarding IBR 
were highest in the Stockholm region, where breast and plastic surgeons have per-
formed breast reconstructions independently or jointly since several decades, sup-
ports this theory. Accordingly, the same should apply to surgeons and their teams 
trained in and familiar with breast-conserving oncoplastic techniques, known to 
increase BCS rates. Again, this hypothesis is supported by the fact that the BCS 
rate was highest in the Stockholm region (once the IBR group was excluded), were 
active training and education in oncoplastic surgery has a long tradition. The lack 
of plastic surgery services in non-university hospitals had a significant impact on 
IBR rates as well as on patient information. This problem could be confronted 
by employing plastic surgeons at or tying them to non-university hospitals on a 
consultancy basis, have more surgical training in oncoplastic and reconstructive 
techniques for breast surgeons, and increase collaboration between breast and 
plastic surgeons (87). 
Some argue that patients with relative risk factors, i.e. factors such as PMRT, 
decreasing the chances for a fully satisfying IBR but not regarded as clear con-
traindications, should not receive full access to and hence information on IBR 
options (88). Several studies describe the undeniable negative effects of PMRT on 
the surgical and cosmetic outcome after IBR (89,90); few reports, however, focus 
on the patients’ perspective. Is it important to remember that when presented with 
the choice of IBR or DBR versus no reconstruction, even after being informed 
of potentially negative effects of PMRT, the majority of women still chose IBR 
(91,92), would choose it again (93), and would recommend it to others (70). This 
should encourage the surgeon to openly discuss advantages and disadvantages of 
each option suitable for the individual patients with her specific preconditions, 
disease characteristics and preferences, and thereby help the patient to make an 
own informed, evidence-based decision. 
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When a patient perceives a lack of information about treatment options, this may 
be due to contributing factors from the informing part (surgeon and other members 
of the breast care team), the receiving part (the patient, her family and friends), or 
from both. In modern times, the patient-surgeon relationship has developed more 
into a shared decision-making and informed consumerist model, where women 
who take a more active role report a higher postoperative satisfaction (65). This 
type of information-seeking behaviour is more common among women with 
a higher level of education (94). Patient participation in the surgical decision-
making process increases postoperative quality of life and patient satisfaction 
compared with a more paternalistic (surgeon-based) decision-making model (58). 
Importantly, this holds true also for the elderly, a subgroup with equally satisfying 
IBR results as in younger patients, who are however less likely to be offered any 
type of reconstruction (95).
When taking a decision for BCS, the travel distance to the nearest hospital may 
play a significant role since adjuvant radiotherapy is a part of the concept of breast 
conservation (96,97). Living at a longer distance from a RT department is associ-
ated with lower BCS rates (98). The RT treatment usually requires 3-5 weeks of 
daily visits, and the effort of daily travel or prolonged overnight stays may affect 
the choice of surgical procedure (99). In our study, however, the North region with 
the longest distances to the next hospital had the second highest BCS rate, and a 
high rate of preoperative information regarding BCS. 
BCS rates were significantly affected by socioeconomic background, even after 
adjusting for other patient and tumour characteristics. This is in line with previ-
ous findings showing the link between higher socioeconomic status and increased 
BCS rates (62,63). The fact that women with a lower socioeconomic status had a 
higher tumour stage has previously been shown (97) and was here confirmed, likely 
influencing surgical choices, too. Patients receiving IBR were socioeconomically 
stronger than all other groups. Commonly, such patients are also less likely to be 
obese, smoke, or have other comorbidities, which would be contraindications for an 
IBR and thus a reason not to inform the patient about reconstruction more in detail 
(58,94,100,101). Unfortunately, such data were not available in the present study.
In other questionnaire-based studies, a higher non-response rate has been seen in 
groups with lower socioeconomic status (102). In an American cohort with different 
types of breast reconstructions, there was a significantly higher non-response rate 
among women of non-white race and low household income (103). In our cohort, 
a majority of the responders had a higher socioeconomic status, which decreases 
the external validity of the results. The inequality in received information and 
involvement would thus, however, have been even more significant if more of the 
non-responders had completed the questionnaire. Results suggest that women with 
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a lower socioeconomic status receive less information or perceive having received 
no or less information; thus, such information should probably be better adapted 
to educational level and health literacy. Even though this demands more flexibility 
in the interaction between the patient and breast care team, it is essential to allow 
the patient to feel involved in the decision-making process (65). If women with a 
lower socioeconomic background do not feel informed about their surgical options 
or supported in their decision, these barriers need to be identified and additional 
support strategies established. For example, standardized information strategies in 
oral, written and visual form are known to improve knowledge (104) of surgical 
treatment options and increases satisfaction with decision-making (105). Take-
home information booklets and online resources for patients to read when feeling 
less distressed might also increase their understanding of available options (106). 
Further measures, such as assigning a dedicated contact nurse and creating national 
information leaflets, have been introduced in Sweden after the evaluation of our 
cohort, and a follow-up study would therefore be of significant interest.
In an immediate two-stage breast reconstruction using tissue expanders, the optimal 
timing of the exchange procedure to a permanent implant (if deemed necessary) 
after completion of PMRT is still debated and mostly based on clinical judgement. 
Exchange can also take place before PMRT without any documented difference 
in complication rates (107). Women not receiving PMRT may exchange their 
expander as early as one month after completed expansion (73,108). The recom-
mended timeline from completion of RT to exchange procedure ranges from three 
to six months (109,110), with a potential benefit in waiting at least six months: 
according to Peled et al, (109) the implant failure rate after implant exchange 
three versus six months after completed RT was 22.4% versus 7.7% (p=0.036). 
In Sweden, the expander-implant exchange procedure is traditionally planned at 
least six months after the radiotherapy completion, which is probably the reason 
why our results could not confirm an effect of time. 
Nodal treatment comprises both lymph node surgery and locoregional RT in 
patients diagnosed with axillary macrometastases in Sweden, which significantly 
increased the risk of implant failure in our study. Scarring and fibrotic changes 
after axillary treatment may disturb the lymphatic drainage from the chest wall, 
leading to increased sensitivity to infection and prolonged wound healing (111). 
Axillary surgery has previously been proven to have a stronger association with 
long-term negative effects such as arm lymphedema than locoregional RT (20), 
an observation which was confirmed by our data on implant failure. 
Unexpectedly, our results showed that even a transitory infection after the initial 
IBR was a strong predictor for implant failure after the subsequent exchange pro-
cedure. A plausible explanation for this could be a lingering subclinical infection, 
in spite of a clinically successful antibiotic treatment, causing capsular contraction 
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due to a presence of re-activated bacteria in the capsular tissue (112). Unfortunately, 
we did not have any information on signs of infection after the revision surgery, 
nor were routine tissue cultures from implant capsule taken, which could have 
reinforced this hypothesis. 
Of all of clinical risk factors identified in study IV, RT, affecting both the adjacent 
muscle and subcutaneous tissues, remained the strongest risk factor for capsular 
contracture. At the interface between the implant and surrounding tissues, there 
is a natural foreign body reaction that contributes to capsular formation by means 
of inflammatory cell infiltration, as demonstrated in study V. High frequencies of 
macrophages and T-cells were identified in capsular biopsies, regardless of radio-
therapy exposure, while B-cell mediated immunity and humoral immune response 
seemed predominantly linked to radiotherapy in the gene expression analysis. 
This was further supported by a significantly more pronounced B-cell infiltration 
in irradiated tissues as assessed by immunohistochemistry. This may support the 
hypothesis that RT can potentiate the foreign body reaction by means of an adap-
tive immune response. B-cells act as antigen-presenting cells for the activation 
of e.g. T-helper cells, which means that more CD40 ligands are expressed on the 
T-helper cells and more cytokines are produced. Theoretically, this could serve as 
an explanation why RT perpetuates a chronic inflammatory response. A chronic 
inflammatory response eventually leads to fibrosis and impaired tissue vascular-
ity (66). This type of late adverse effect caused by RT may further explain why 
previously administered RT has been identified as a strong risk factor for implant 
surgery complications (70). In those cases, the irradiated tissue may need to be 
replaced by non-irradiated tissue transferred from other parts of the body as an 
autologous reconstruction, e.g. a DIEP flap. However, in study IV, we excluded 
implants removed due to conversion to autologous reconstructions since the under-
lying reasons of implant removal was not only related to surgical complications, 
but sometimes related to the patient’s wish or an inferior cosmetic result which 
is often related to capsular contracture. Further investigation of infiltration of 
immune cells around breast implants, with or without RT, could contribute to the 
development of therapeutic strategies to attenuate capsular formation.
Strengths and limitations
Study I-III
There is always a risk of recall bias in any retrospective study design (113), which 
should, however, have been equally distributed over the compared groups. Further, 
no data on risk factors such as comorbidity, high BMI and smoking were available, 
which might nevertheless have influenced the surgical decision-making process. 
Since our results stem from 2013, they could be viewed as outdated consider-
ing that BCS and IBR rates have significantly improved since we conducted our 
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 studies; subsequent national reports, however, continue to show regional differences 
despite an increased national IBR rate (4). The main strengths of studies I-III are 
the high coverage and validity of two national registers containing detailed clini-
cal and socioeconomic information, as well as the fact that patient perspectives 
were integrated into analyses with a high response rate (85,86). Moreover, the 
impact of socioeconomic background is especially interesting in a country with 
tax-funded healthcare guaranteeing equal care to all citizens, since the influence 
of reimbursement should be negligible as a confounder.
Study IV
In most retrospective studies based on medical chart reviews, there is a risk of 
limited information since the viewer can only register data that have been recorded 
by others without any standardized data requirements. This, however, was not 
true for the main outcome since reoperations are always registered in the medical 
charts by means of standardized codes. Even though our studied cohort was large, 
there was a surprisingly low number of events, which rendered advanced statistical 
analyses inappropriate. Furthermore, overall implant removal rates would have been 
higher if we had included implant removal due to discomfort or inferior cosmetic 
results, often resulting in a conversion to an autologous reconstruction; this was, 
however, not the aim of our evaluation. It would be an interesting future addition 
to our study to also evaluate such conversion rates since these should most likely 
vary with the receipt of RT, too. 
Study V
Due to the rather small sample size, gene expression results need to be interpreted 
with some caution. The overall RNA quality was low, which shows the difficulties 
of preparing sensitive tissues in a clinical environment. The lack of inter-individual 
differences may be due to no paired cases with a non-irradiated control. Paired 
synchronized samples of irradiated biopsies and non-irradiated internal controls 
could have isolated RT effects, which was however not possible in this study.
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6 CONCLUSIONS
In summary, we provide explanatory models for variations in BCS and IBR rates 
in Sweden. Surgical choices were affected by socioeconomic factors, and patient-
reported preoperative information and involvement in the decision-making pro-
cess proved to be strong predictors even after adjusting for other covariates. Our 
results suggest that socioeconomic background should be taken into account in 
preoperative counselling, to provide tailored information and equal health care 
to all individuals.
PMRT was confirmed as a risk factor for implant failure after revision surgery; 
we could, however, not identify an effect of the time elapsed from completion 
of PMRT. In addition to known risk factors such as diabetes or smoking, special 
attention should be paid to previous axillary lymph node dissection and a history 
of post-IBR infection. Failure rates following revision surgery after IBR, however, 
are low, so that it appears to be an acceptable option even in the irradiated breast. 
For a growing population of women receiving PMRT, it is of paramount impor-
tance to better understand the biology behind radiation-induced capsular contrac-
ture in order to pave way for future therapeutic and prophylactic strategies. We 
revealed inflammatory responses in capsular biopsies regardless of RT, while the 
radiation response specifically involved B-cells. We encourage future search for 
therapeutic treatment strategies to attenuate capsular contracture and its severe 
clinical consequences in patients undergoing implant-based breast reconstruction.
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